X

Trial Profile

A phase I first-in-human study of RLS-1496

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 22 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RLS-1496 (Primary)
Indications Atopic dermatitis; Psoriasis
Focus Adverse reactions; First in man
Sponsors Rubedo Life Sciences

Most Recent Events

16 Jan 2025 According to a Rubedo Life Sciences media release, the company announced Phase 1 clinical trial for RLS-1496 will begin in Spring 2025 in the Netherlands and the kickoff of the companys Series B financing round.
16 Jan 2025 According to a Rubedo Life Sciences media release, the company announced its clinical development plans for RLS-1496 at the 12th Annual Dermatology Summit.
23 Oct 2024 According to a Rubedo Life Sciences media release, company announced the opening of their European headquarters and clinical operations in Milan.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com